{"id":55549,"date":"2022-12-22T14:39:03","date_gmt":"2022-12-22T14:39:03","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=media_gallery&p=55549"},"modified":"2022-12-22T14:39:03","modified_gmt":"2022-12-22T14:39:03","slug":"mafalda-oliveira-sabcs-2022-camizestrant-vs-fulvestrant-in-women-with-advanced-er-her2-breast-cancer-the-serena-2-trial","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/breast-cancer\/conference-hub\/mafalda-oliveira-sabcs-2022-camizestrant-vs-fulvestrant-in-women-with-advanced-er-her2-breast-cancer-the-serena-2-trial\/","title":{"rendered":"Mafalda Oliveira, SABCS 2022: Camizestrant vs fulvestrant in women with advanced ER+ HER2- breast cancer: The SERENA-2 trial"},"content":{"rendered":"

The SERENA-2 trial (NCT04214288)<\/a> is a randomised, multicentre phase II trial evaluating camizestrant at several dose levels compared to fulvestrant in advanced ER-positive, HER2-negative breast cancer. In this touchONCOLOGY interview, we speak with <\/span>Dr\u00a0Mafalda Oliveira <\/b>(Vall d\u2019Hebron University Hospital Barcelona, Spain) who gives an overview of the SERENA-2 trial and the advantages<\/span> for the use of camizestrant over fulvestrant <\/span>as well as discussing the next steps in the clinical development of camizestrant.<\/span><\/span><\/p>\n

The abstract entitled \u2018Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial<\/span><\/span>\u2019 was presented at San Antonio Breast Cancer Symposium\u00a0(SABCS)<\/a>, 06\u201310, December, 2022.<\/span><\/p>\n

Questions<\/b>:<\/span><\/p>\n

    \n
  1. What is camizestrant and what are its potential advantages over fulvestrant in the treatment of post-menopausal women with advanced ER-positive HER2-negative breast cancer? (0:18)
    \n<\/span><\/li>\n
  2. What were the aims, design and eligibility criteria of the SERENA-2 trial? (1:18)
    \n<\/span><\/li>\n
  3. What was the primary endpoint and how well was it achieved across the pre-specified subgroups of urgent medical need? (2:39)
    \n<\/span><\/li>\n
  4. What were the safety and tolerability findings? (4:43)
    \n<\/span><\/li>\n
  5. What will be the next steps in the clinical development of camizestrant? (5:43)<\/span><\/li>\n<\/ol>\n

    Disclosures<\/b>: Mafalda Oliveira is a consultant for AstraZeneca, GuardantHealth, Roche, MSD, Relay Therapeutics, Pfizer, SeaGen, iTEOS and Gilead and discloses grant\/research support from AstraZeneca, Ayala Pharmaceuticals, Boehringer-Ingelheim, Genentech, GSK, Novartis, PUMA Biotechnology, Roche, SeaGen and Zenith Epigenetics.<\/span><\/p>\n

    Support<\/b>: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen<\/span><\/p>\n

    Filmed as a highlight of <\/i><\/b>SABCS 2022<\/i><\/b><\/a><\/p>\n

    Access more content on Breast Cancer<\/a><\/i><\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

    The SERENA-2 trial (NCT04214288) is a randomised, multicentre phase II trial evaluating camizestrant at several dose levels compared to fulvestrant in advanced ER-positive, HER2-negative breast cancer. In this touchONCOLOGY interview, we speak with Dr\u00a0Mafalda Oliveira (Vall d\u2019Hebron University Hospital Barcelona, Spain) who gives an overview of the SERENA-2 trial and the advantages for the use […]<\/p>\n","protected":false},"featured_media":55590,"template":"","class_list":["post-55549","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-breast-cancer","video_categories-sabcs-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/55549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":5,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/55549\/revisions"}],"predecessor-version":[{"id":55630,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/55549\/revisions\/55630"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media\/55590"}],"wp:attachment":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media?parent=55549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}